{"id":928442,"date":"2026-01-20T06:04:32","date_gmt":"2026-01-20T11:04:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\/"},"modified":"2026-01-20T06:04:32","modified_gmt":"2026-01-20T11:04:32","slug":"nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\/","title":{"rendered":"Natera\u2019s Fetal Focus\u2122 Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting"},"content":{"rendered":"

<\/p>\n

Natera\u2019s Fetal Focus\u2122 Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting<\/b><\/p>\n

EXPAND clinical trial to be presented; data support Fetal Focus\u2122 sgNIPT for inherited conditions<\/i><\/p>\n

AUSTIN, Texas–(BUSINESS WIRE<\/a>)–Natera, Inc.<\/a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the EXPAND clinical trial will be featured in an oral plenary presentation at the SMFM meeting, taking place February 8-13, 2026.<\/p>\n

\nEXPAND is a prospective, blinded clinical trial to develop and validate Fetal Focus. Powered by Natera\u2019s proprietary, ultra-sensitive LinkedSNP\u2122 technology, Fetal Focus assesses whether a fetus has inherited disease-causing variants from one or both parents, analyzing 21 genes associated with serious, early-onset medical conditions.<\/p>\n

As previously announced<\/a>, EXPAND validated Fetal Focus\u2019 ability to identify a broad range of clinically relevant inherited conditions with high accuracy. The oral presentation will detail the study\u2019s key results, along with its robust design, including confirmation of all outcomes against genetic truth.<\/p>\n

\n\u201cBeing selected for a plenary session at SMFM highlights the high quality of the EXPAND data and its role in advancing prenatal screening,\u201d said Sheetal Parmar, M.S., CGC, senior vice president of medical affairs for women\u2019s health at Natera. \u201cSupporting women\u2019s health is central to Natera\u2019s mission. EXPAND reflects our ongoing commitment to generating high-quality clinical evidence that delivers actionable insights in prenatal care.\u201d<\/p>\n

\nIn addition to EXPAND, Natera and its collaborators will deliver a second oral presentation at SMFM highlighting data from VANISH, a prospective clinical trial which validates the unique ability of Panorama\u2122 NIPT to interpret cell-free DNA patterns in vanishing twin pregnancies.<\/p>\n

The full list of Natera presentations at SMFM includes:<\/b><\/p>\n

February 11, 8:45 AM PT | Presentation # 4 (Oral Plenary Presentation)
\n
<\/b>Presenter: Rajeevi Madankumar, M.D.
\n
Performance of a single gene non-invasive prenatal screening test for recessive conditions<\/i><\/p>\n

February 11, 10:30 AM PT | Presentation # 145 (Poster)
\n
<\/b>Presenter: Vivienne Souter, M.D.
\n
Carrier Screening as a Pathway to In-Utero Therapy<\/i><\/p>\n

February 12, 1:00 PM PT | Presentation # 65 (Oral Presentation)
\n
<\/b>Presenter: Lorraine Dugoff, M.D.
\n
Development and Validation of a SNP-based cfDNA test for vanishing twin pregnancies: The VANISH Trial<\/i><\/p>\n

February 12, 3:30 PM PT | Presentation # 1092 (Poster)
\n
<\/b>Presenter: Jeffrey T. Meltzer, M.D.
\n
Identification of maternal Alzheimer\u2019s disease risk after an atypical finding on SNP-based prenatal cfDNA screening<\/i><\/p>\n

About Natera<\/b><\/p>\n

\nNatera\u2122 is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women\u2019s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera\u2019s tests are supported by more than 350 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com<\/a>.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nAll statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera\u2019s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera\u2019s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in “Risk Factors” in Natera\u2019s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com\/investors<\/a> and www.sec.gov<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260120290888\/en\/<\/a><\/span><\/p>\n

\nInvestor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com
\n<\/a>
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com<\/a><\/p>\n

KEYWORDS:<\/b> Texas United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Women Baby\/Maternity Genetics Clinical Trials Other Health Biotechnology General Health Consumer Health Oncology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Natera\u2019s Fetal Focus\u2122 Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting EXPAND clinical trial to be presented; data support Fetal Focus\u2122 sgNIPT for inherited conditions AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the EXPAND clinical trial will be featured in an oral plenary presentation at the SMFM meeting, taking place February 8-13, 2026. EXPAND is a prospective, blinded clinical trial to develop and validate Fetal Focus. Powered by Natera\u2019s proprietary, ultra-sensitive LinkedSNP\u2122 technology, Fetal Focus assesses whether a fetus has inherited disease-causing variants from one or both parents, analyzing 21 genes associated with serious, early-onset medical conditions. As previously … <\/p>\n

Continue reading “Natera\u2019s Fetal Focus\u2122 Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-928442","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNatera\u2019s Fetal Focus\u2122 Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Natera\u2019s Fetal Focus\u2122 Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Natera\u2019s Fetal Focus\u2122 Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting EXPAND clinical trial to be presented; data support Fetal Focus\u2122 sgNIPT for inherited conditions AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the EXPAND clinical trial will be featured in an oral plenary presentation at the SMFM meeting, taking place February 8-13, 2026. EXPAND is a prospective, blinded clinical trial to develop and validate Fetal Focus. Powered by Natera\u2019s proprietary, ultra-sensitive LinkedSNP\u2122 technology, Fetal Focus assesses whether a fetus has inherited disease-causing variants from one or both parents, analyzing 21 genes associated with serious, early-onset medical conditions. As previously … Continue reading "Natera\u2019s Fetal Focus\u2122 Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-20T11:04:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260120290888r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Natera\u2019s Fetal Focus\u2122 Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting\",\"datePublished\":\"2026-01-20T11:04:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\\\/\"},\"wordCount\":759,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260120290888r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\\\/\",\"name\":\"Natera\u2019s Fetal Focus\u2122 Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260120290888r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-01-20T11:04:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260120290888r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260120290888r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Natera\u2019s Fetal Focus\u2122 Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Natera\u2019s Fetal Focus\u2122 Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Natera\u2019s Fetal Focus\u2122 Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting - Market Newsdesk","og_description":"Natera\u2019s Fetal Focus\u2122 Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting EXPAND clinical trial to be presented; data support Fetal Focus\u2122 sgNIPT for inherited conditions AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the EXPAND clinical trial will be featured in an oral plenary presentation at the SMFM meeting, taking place February 8-13, 2026. EXPAND is a prospective, blinded clinical trial to develop and validate Fetal Focus. Powered by Natera\u2019s proprietary, ultra-sensitive LinkedSNP\u2122 technology, Fetal Focus assesses whether a fetus has inherited disease-causing variants from one or both parents, analyzing 21 genes associated with serious, early-onset medical conditions. As previously … Continue reading \"Natera\u2019s Fetal Focus\u2122 Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-20T11:04:32+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260120290888r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Natera\u2019s Fetal Focus\u2122 Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting","datePublished":"2026-01-20T11:04:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\/"},"wordCount":759,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260120290888r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\/","name":"Natera\u2019s Fetal Focus\u2122 Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260120290888r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-01-20T11:04:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260120290888r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260120290888r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nateras-fetal-focus-single-gene-nipt-sgnipt-selected-for-prestigious-oral-plenary-presentation-at-society-of-maternal-fetal-medicine-smfm-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Natera\u2019s Fetal Focus\u2122 Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/928442","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=928442"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/928442\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=928442"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=928442"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=928442"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}